Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has announced that it has filed a lawsuit against India's Ranbaxy Laboratories for "willful infringement" of patents protecting the company's heartburn and ulcer medication, Nexium.
Subscribe to our email newsletter
The lawsuit is in response to an abbreviated new drug application filed by Ranbaxy with the FDA to market a generic version of Nexium in the US prior to the expiration of six AstraZeneca patents covering the drug. Expiration dates for the patents range from 2014 through 2019.
“AstraZeneca has full confidence in and will continue vigorously to defend and enforce its intellectual property rights protecting Nexium,” said an AstraZeneca statement.
Earlier this month, AstraZeneca filed a similar suit against Israel’s generic drug maker Teva Pharmaceuticals for infringement of a patent covering Seroquel, a treatment for schizophrenia, after Teva filed an abbreviated new drug application with the FDA for a copycat version of the drug. According to AstraZeneca, the patent covering Seroquel does not expire until 2011.